Dianthus Therapeutics (DNTH) Insider Trading & Ownership $20.11 +0.23 (+1.16%) As of 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Dianthus Therapeutics (NASDAQ:DNTH) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.56%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$1.31 MNumber OfInsiders Selling(Last 3 Years)0 Get DNTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Dianthus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address DNTH Insider Buying and Selling by Quarter Dianthus Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/29/2023Fairmount Funds Management LlcDirectorBuy24,670$13.63$336,252.10 9/26/2023Fairmount Funds Management LlcDirectorBuy30,000$13.15$394,500.00 9/21/2023Simrat RandhawaInsiderBuy2,000$13.20$26,400.00 9/19/2023Fairmount Funds Management LlcDirectorBuy30,000$13.20$396,000.00 9/12/2023Fairmount Funds Management LlcDirectorBuy14,887$10.85$161,523.95 (Data available from 1/1/2013 forward) DNTH Insider Trading Activity - Frequently Asked Questions Who is on Dianthus Therapeutics's Insider Roster? The list of insiders at Dianthus Therapeutics includes Fairmount Funds Management Llc, and Simrat Randhawa. Learn more on insiders at DNTH. What percentage of Dianthus Therapeutics stock is owned by insiders? 16.56% of Dianthus Therapeutics stock is owned by insiders. Learn more on DNTH's insider holdings. Which Dianthus Therapeutics insiders have been buying company stock? The following insiders have purchased DNTH shares in the last 24 months: Fairmount Funds Management Llc ($1,288,276.05), and Simrat Randhawa ($26,400.00). How much insider buying is happening at Dianthus Therapeutics? Insiders have purchased a total of 101,557 DNTH shares in the last 24 months for a total of $1,314,676.05 bought. Dianthus Therapeutics Key ExecutivesMr. Marino Garcia M.B.A. (Age 58)President, CEO, Secretary & Director Compensation: $496.02kMr. Ryan Savitz (Age 35)CFO and Chief Business Officer & Treasurer Compensation: $329.65kMr. Simrat Randhawa M.B.A. (Age 54)M.D., Chief Medical Officer Compensation: $338.16kMr. Edward G. Carr (Age 55)Chief Accounting Officer Mr. Judson TaylorHead of Technical OperationsDr. Jeffrey Stavenhagen Ph.D.Chief Scientific OfficerMs. Jennifer Davis RuffVP and Head of Investor Relations & Corporate Affairs.Mr. Adam M. Veness Esq. (Age 38)Senior VP, General Counsel & Secretary Ms. Kristina MaximenkoChief People OfficerMs. Rashieda GluckHead of Clinical Development Operations More Insider Trading Tools from MarketBeat Related Companies Zai Lab Insider Trades Bausch Health Companies Insider Trades Recursion Pharmaceuticals Insider Trades Catalyst Pharmaceuticals Insider Trades Gemini Therapeutics Insider Trades Twist Bioscience Insider Trades Edgewise Therapeutics Insider Trades Amneal Pharmaceuticals Insider Trades Kymera Therapeutics Insider Trades Janux Therapeutics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:DNTH) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts